Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium Respimat in children with bronchopulmonary dysplasia
2020-000529-19Phase 2Terminated
- Sponsor
- Technische Universität Dresden
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tiotropium in bronchopulmonary dysplasia (BPD) (2 arms), sponsored by Technische Universität Dresden. Primary endpoint: Change in FEV1 peak (0-1 h) after 12 weeks of treatment. Started Jul 2020; status: terminated.
02
Drugs
tiotropium
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on 2020-000529-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000529-19.